2024 World Conference on Lung Cancer (WCLC) - Posters-P3.13D.06 Distinct Single-Cell Transcriptomic Characteristics and Responses to the Front-Line Therapy in Patients with Central or Peripheral ES-SCLC

P3.13D.06 Distinct Single-Cell Transcriptomic Characteristics and Responses to the Front-Line Therapy in Patients with Central or Peripheral ES-SCLC

Back to course

Pdf Summary

The study, "Distinct Single-Cell Transcriptomic Characteristics and Responses to the Front-Line Therapy in Patients with Central or Peripheral ES-SCLC," investigates the unique characteristics of tumoral and microenvironmental features in extensive-stage small-cell lung cancer (ES-SCLC). This type of cancer is known for its very poor prognosis, and current treatments like chemotherapy alone or combined with immune checkpoint inhibitors (ICIs) lack effective biomarkers for predicting efficacy.<br /><br />The researchers utilized single-cell RNA sequencing (scRNA-seq) to differentiate between peripheral and central ES-SCLC. Initial analyses were conducted on nine treatment-naïve tumor tissues. The findings from these analyses were validated with a retrospective clinical cohort of 265 patients who received chemotherapy or chemo-immunotherapy as the first line of therapy.<br /><br />The study found that peripheral ES-SCLC has distinct characteristics compared to the central type. It is more resistant to chemotherapy but benefits more from the addition of ICI to chemotherapy compared to central ES-SCLC. The analysis showed that peripheral ES-SCLC exhibits chemo-resistant and ICI-supporting single-cell traits, resulting in a poorer response to chemotherapy compared to the central type.<br /><br />The research highlights the need for further investigation into the cellular or molecular mechanisms that account for the differences between peripheral and central ES-SCLC. The study also suggests that larger clinical cohort studies are necessary to verify these findings. This research makes a significant contribution to the exploration of potential biomarkers that could improve prediction and efficacy in treating ES-SCLC, particularly for the peripheral subtype.

Asset Subtitle

Libo Luo

Meta Tag

Speaker Libo Luo

Topic SCLC & Neuroendocrine Tumors

Keywords

single-cell transcriptomics

ES-SCLC

tumoral characteristics

microenvironmental features

chemotherapy

immune checkpoint inhibitors

scRNA-seq

peripheral vs central ES-SCLC

chemo-resistance

biomarkers